Internet for Pharmaceutical and Biotech Communities
| Newsletter | Post Jobs | Advertising |
 
 
 

  

Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 
   



 

Title:  Method for modulating nerve cell function
United States Patent: 
7,005,411
Issued: 
February 28, 2006
Inventors: 
Goodman; Corey S. (Berkeley, CA); Kidd; Thomas (Berkeley, CA); Tear; Guy (London, GB); Russell; Claire (London, GB); Mitchell; Kevin J. (San Francisco, CA)
Assignee: 
Regents of the University of California (Oakland, CA)
Appl. No.: 
191651
Filed: 
November 13, 1998


 

Web Seminars -- Pharm/Biotech/etc.


Abstract

The amount of active Robo expressed on a cell is modified by modulating the effective amount of a Comm polypeptide in contact with the cell, whereby the amount of expressed active Robo is modulated inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. In a particular embodiment, the Comm polypeptide is provided to the cell by exogenously in a pharmaceutically acceptable composition. In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell.

SUMMARY OF THE INVENTION

The invention provides methods and compositions for modulating the amount of active Robo expressed on a cell. The general method involves modulating the effective amount of a Comm polypeptide in contact with a cell expressing an amount of active Robo polypeptide, whereby the amount of expressed active Robo is modulated inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. For example, where the effective amount of the Comm polypeptide is increased, the amount of expressed Robo is decreased. The Robo polypeptide is preferably a human, mouse, C. elegans or Drosophila Robo I or II sequence or a polypeptide domain thereof having a Robo-specific activity, and the Comm polypeptide specifically modulates Robo expression and (a) comprises SEQ ID NO:14 or a deletion mutant thereof which specifically modulates Robo expression and/or (b) is encoded by a nucleic acid comprising SEQ ID NO:13 or a nucleic acid which hybridizes with SEQ ID NO:13, preferably under stringent conditions. In a particular embodiment, the Comm polypeptide is provided to the cell exogenously in a pharmaceutically acceptable composition. In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell.

DETAILED DESCRIPTION OF THE INVENTION

The subject methods involve modulating the effective amount of a Comm polypeptide in contact with a cell expressing an amount of active Robo polypeptide, whereby the amount of expressed active Robo is modified inversely with the modulation of the effective amount of the Comm polypeptide in contact with the cell. Robo expression is found to regulate a wide variety of cell functions, including cell-cell interactions, cell mobility, morphology, etc. Accordingly, the invention provides methods for modulating targeted cell function comprising the step of modulating Robo expression by contacting the cell with a Comm polypeptide.

The targeted Robo polypeptide is generally naturally expressed on the targeted cells. The nucleotide sequences of exemplary natural cDNAs encoding drosophila 1, drosophila 2, C. elegans, human 1, human 2 and mouse 1 Robo polypeptides are shown as SEQ ID NOS:1, 3, 5, 7, 9, 15-16 and 11, respectively, and the full conceptual translates are shown as SEQ ID NOS:2, 4, 6, 8, 10, 17-18 and 12. The targeted Robo polypeptides comprise at least a functional domain of SEQ ID NOS:2, 4, 6, 8, 10, 17-18 and 12, which domain has Robo-specific amino acid sequence and binding specificity or function. Preferred Robo domains comprise at least 8, preferably at least 16, more preferably at least 32, most preferably at least 64 consecutive residues of one of these SEQ ID NOS. In a particular embodiment, the domains comprise one or more structural/functional Robo immunoglobulin, fibronectin or cytoplasmic motif domains described herein. The subject domains provide Robo-specific antigens and/or immunogens, especially when coupled to carrier proteins. For example, peptides corresponding to Robo- and human Robo-specific domains are covalently coupled to keyhole limpet antigen (KLH) and the conjugate is emulsified in Freunds complete adjuvant. Laboratory rabbits are immunized according to conventional protocol and bled. The presence of Robo-specific antibodies is assayed by solid phase immunosorbant assays using immobilized Robo polypeptides of SEQ ID NO:2, 4, 6, 8, 10, 17-18 or 12. Generic Robo-specific peptides are readily apparent as conserved regions in the aligned Robo polypeptide sequences of Table 1.

TABLE 1
 
Sequence Alignment of Robo Family Members: The complete amino acid
alignment of the predicted Robo proteins encoded by drosophilia robo
1 (D1, SEQ ID NO:2) and Human robo 1 (H1, SEQ ID NO:8) are shown.
The extracellular domain of C. elegans robo (CE, SEQ ID NO:6;
Sax-3; Zallen et al., 1997), the extracellular domain of Drosophila robo
2 (D2, SEQ ID NO:4), and partial sequence of Human robo 2
(H2, SEQ ID NO:10) are also aligned. The D2 sequence was predicted by
the gene-finder program Grail. The position of immunoglobulin domains
(Ig), fibronectin domains (FN), the transmembrane domain (TM), and
conserved cytoplasmic motifs are indicated. The extracellular domain of
rat robo 1 is nearly identical to H1.
 
 
mH.............PMHpENHAIaRSTSTTNNPSrsRSSRMWLlpAWLLLVLVASNGLP 47 D1
m.FNRKTLlCTi.llVlQA..............vIrsFCEDASNlA.............. 30 CE
mKWKHVPFlVMiSllSlSpNHLFLaQLIPDPEDvErG.NDHGTPIpTSDNDDNSLGYTGS 59 H1
        >IG #1
AVrGQYQSpriiehpTdlvvKknepatlnckVegKpEptiewfkdgepvStn..EKKshr 105 D1
     GENpriiehpMdTTvPknDpFtFncQaegNptptiQwfkdgRELKt...dTGshr   D2
........pViiehpIdVvvsRgSpatlncGaK.PStAKiTwykdgQpvItnkEQVNshr 81 CE
RLrQEDFPpriVehpSdlIvskgepatlnckaegRptptiewykGgeRvEtDkDdPRshr 119 H1
                                         
VQFKDgAlffYriMQgkkeQ..dGgEywcvaknRVgQavsrHaslqIavlrddfrvepKd 163 D1
iMlpAgGlfflkvIhSrReS..dagTywcEakneFgVaRsrnaTlqvavlrdEfrLepAN   D2
iVlDTgslfLlkvNSgkNGKDSdagAyYcvaSneHgeVKsNEGslKLaMlrEdfrvRpRT 141 CE
MLlpSgslfflriVhgrkSRP.dEgVyVcvaRnYLgeavsHnaslEvaIlrddfrQNpSd 178 H1
trvaKgeTallecgppKgIpeptLIwIkdgVplddLKAmSFGASSrVrivdggnlLiSNv 223 D1
trvaQgeValmecgAprgSpepQiswrkNgQTlNL......VGNKririvdggnlAiQEA   D2
vQALGgeMavlecSpprgFpepVVswrkdDKElRI.QDmP.....rYTLHSDgnlIiDPv 195 CE
vMvaVgePavmecQpprgHpeptiswKkdgSpldd.......KDEri.TIRggKlMiTYT 230 H1
                             >IG #3
EPIdEgNyKcIaQnLvgtresSYaKlIvQvkpYfMkepkdqVMLYgQTaTfHcSvggdpP 283 D1
rQsdDgRyqcvVKnVvgtresATaFlKvHvrpFLIRGpQnqtAVvgSsvVfQcrIggdpL   D2
DRsdSgTyqcvaNnmvgerVsNPaRlSvFekpKfEQepkdMtvDvgAAvLfDcrvTgdpQ 225 CE
rKsdAgKyVcvGTnmvgeresEVaElTvLerpSfVkRpSnLAvTvDDsaEfKcEARgdpV 290 H1
pKvlwkk..EEgnIpvsrA..........RiLHdEKslEiSNItpTdegTyvceaHnNvg 331 D1
pDvlwrrTASGgnmpLRKFSWLHSASGRVHVl.EdrslkLDDvtLEdmgeytceaDnAvg   D2
pQITwkr..KNEPmpvTra..........YiAKdNrGlRiERvQpSdegeyvcYaRnPAg 303 CE
pTvRwrk..DDgELpKsrY..........Ei.RddHTlkiRKvtAGdmgSytcVaEnMvg 337 H1
             >IG #1
QiSaRaSlIvhappNfTKrpSnKKvGlNgVvQLPcMaSgnpPpSvfwTkegVSTlMfpn. 388 D1
GiTaTGIltvhappKfvIrpKnqLvEIgDEvLfecQaNgHpRpTLYwsVegNSSllLpGy   D2
TLeasaHlRvqappSfQTkpAdqSvPAggtAtfecTLVgQpSpaYfwskegQqDllfpsy 363 CE
KAeasaTltvqEppHfvVkpRdqVvalgrtvtfQceaTgnpqpaIfwRRegsqnllf.sy 396 H1
                      qIvaQgrtvtfPceTKgnpqpavfwQkegsqnllfpn.   H2
...SsHGrQYvAADgtlQitDvrqedegyyv.cSaFSvvDssTVrVFlQvSS..vD.... 440 D1
RDGRMEVTLTPEGRSVlSiARFAredSgKVvTcNalnAvgsVSsrTVVSvDt..QF....   D2
VSADGRTK..vsptgtltiEEvrqVdegAyv.cAGMnSagsslskaAlKvttKAvTGNTP 420 CE
qpPQsSsrFsvsQtgdltitnvqrsdVgyyi.cqTlnvagsiITkaYlevtd..vIA... 450 H1
qpQQPNsrCsvsptgdltitnIqrsdAgyyi.cqalTvagsilAkaQlevtd..vLT...   H2
>IG #5
erpppiiQIgpAnqtlpKgsVaTlpcratgNpSpRiKwFHdgHAvQA.GNRYSi.iqG.. 496 D1
eLpppiieqgpvnqtlpvKsIVvlpcrTLgTpvpQVswYLdgIpidVqEHERrNLsDA..   D2
AKpppTieHgHQnqtlMvgsSaIlpcQaSgKpTpGiswlRdgLpidITd..sri.sqHST 477 CE
drpppViRqgpvnqtVavdgtFvlScVatgSpvpTiLwRkdgVLvSTqd..sriK.qLeN 507 H1
drpppiiLqgpAnqtlavdgtaLcKcKatgDpLpViswlkEgFTFPGRd..PrATiq.eQ   H2
                                       >FN #1<
SslRVDdlq.lsdSgtytciasGeRgeTswAaTltveKpgs..TSLHraAdpstypAppg 553 D1
gAlTiSdlqrHEdEgLytcvasnRNgKsswsGylRLDTptNpNiKfFrapElstypgppg   D2
gslHiAdl.kKPdtgVytciaKneDgestwsaSltveDHtsN.AqfVrMpdpsNFpsSpT 535 CE
gvlqiR.YAklGdtgRytciasTPsgeatwsayIEvQeFgVp.VqPPrPTdpNLIpsAps 565 H1
gTlqiKNl.rIsdtgtytcvaTSSsgeaswsaVlDvTeSgAT.i..SKNYdlsDLpgpps   H2
TpKvLnvsrtsISlRwAKSqEKPGAVgpIi.gyTVeyfspdlQTgwIVAaHrvGDtQVti 612 D1
kpqMvEKGEnsvtlsw...TRSNKVggSSLVgyVieMfGKNETDgwVAvGTrvQNttFtQ   D2
QpIIvnvtDtEvElHw...NAPSTsgaGpitgyiiQyYspdlgQTwFNIPDYvAStEyRi 592 CE
kpEvtdvsrnTvtlsw...qpNLNsgaTp.tSyiieafsHASgSswqtvaENvktEtSAi 621 H1
kpqvtdvtKnsvtlsw...qpGTPGTLpA.SAyiieafsQSVSNswqtvaNHvkttLytV   H2
                       >FN #2
SglTpgtsyVflvraenTQgisvpsGLsNViktIEA....DfDAASANdlsAarT.llTg 667 D1
TglLpgVNyFfliraenSHgLsLpsPMsEpitVGTR....YfNS..gLdlsEarASllsg   D2
kglkpSHsyMfViraenEkgiGTpsVSsALvttSKPAAQVAlSDKNKMdMAIaEKRlTsE 652 CE
kglkpnAiylflvraAnAYgisDpsqIsDpvktQDV.....lPTSQgVdHKQVQRE.lGN 675 H1
RglRpntiylfMvraInPkV.svT.q   H2
KSvelIDasAinAsavrlEwMLHvSADEkyvegLRiHyK..DaSVPSAQYHSITvMDAsa 725 D1
DvvelSnasvVDstsMKlTwQI...INGkyvegFyVYArQLpNPLNTKyRMLTILNGGGa   D2
QLIKlEEVKTinstavrlFwKKR..KLEELiDgyyiKWrGPpRTNDNQyVN...vTSpsT 707 CE
AvLHlHnPTvLSsssIEVHwT..vDQQSQyiQgyKiLyrPSGaNHGESDWLVFEvRTpAK 733 H1
                               >FN #3
esFvvGnlKkytKyeffLTpf...fETiegQpsnskTaltYedvpsappDNIQiGmYn.. 780 D1
SsCTiTGlVQytLyeffIVpf...YKsVegKpsnsRIaRtledvpsEApYgMEALLln..   D2
eNYvvSnlMPFtnyeffVIpYHSGVHsiHgapsnsMDVltAeAPpsLppEDvRiRmlnL. 766 CE
NsVviPDlRkGVnyeIKARpf...fNEFQgaDsEIkFaKtleEApsappQgvTVSKNDGN 790 H1
QtaGWvRwTpppSQHHngNlYgykiEVSAgnTM.....KVlAnMtLnaTtTsvLlNnltt 835 D1
SSaVFLKwkapELKDRHgVlLNyH.vivRgIDtAHNFSRIlTnVtIdaASPTLvlAnltE   D2
.tTLRIswkapKAdGIngIlKgFQiviv.gQAPNNNR.....nItTnERAAsvTlFHlVt 819 CE
GtaILvswQpppEdTQngMVQEykV.WCLgnEtR.....YHInKtVdGStFsvvIPFlVP 844 H1
                   <
gAVysvrLNSFtKagDgpysKpISlFMdpTHHVHPpRAHPsGTHDGRHEGqDLTYHNNgN 895 D1
gVMyTvGvaaGNnagvgpyCVpATlRldpITKRLDpFINQRDHVND..............   D2
gMTyKIrvAARSnGgvgv..........ShgTSEVIMNqDTlEKHL.AAQqENESFLYgL 868 CE
gIRysvEvaaStGagSgvKsEpQFIQldAhgNPVSpEDqVslAQQI.............. 890 H1
                >             TM          &nbs
iPPGDINPTTHKKTTdYlSGpwLMViVCiVlLvlVisAAIsM.vyFkrkhQmTKElGHLS 954 D1
................vlTqpwFIiiLgAilavlMLs..fGAMvFVkrkhMm..MkQsAL   D2
iNK..............SHVpVIViVaILiIFvViiIAY.CYwRNS.rNSD...gkDRSF 909 CE
..............SdvVKqp..AFiagiGAaCWiiLMVfsIwLyRHrkKR..NglTsTY 932 H1
VVSDNEIT.......................AlniNSKESL.wIDHHRGwRTADTDKD.. 988 D1
AGIRKVPSFTFTPTVTYQRGGEAVSSGGRPGLlniSEPAAQPwLAD..TwPNTGNNHNDC 990 H1
........SgLsEsKlLSHVNSSQ..SnynnS..........DGGtDyAEvd....TRNL 1024 D1
SISCCTAGNgNsDsNlTTYSRPADCIAnynnQLDNKQTNLMLPEStVyGDvdLSNKINEM 1050 H1
              CYTOPLASMIC MOTIF #1
TtfYNCR.......KSPDNptpyattMIiGTS........sSETCTkT.TSISADkDSGT 1068 D1
KtfNSPNLKDGRFVNPSGQptpyattQLiQSNLSNNMNNGsGDSGEkHWKPLGQQkQEVA 1110 H1
HSPyS........DAFAGQVPAVpVV..KSNyLqYPVEP..................... 1097 D1
PVQyNIVEQNKLNKDYRANDTVPpTIPYNQSyDqNTGGSYNSSDRGSSTSGSQGHKKGAR 1170 H1
        CYTOPLASMIC MOTIF #2
.........InwSEFlppppEhppp...sSTy......GyAqGSp............... 1124 D1
TPKVPKQGGMnwADLlppppAhpppHSNsEEyNISVDESyDqEMpCPVPPARMYLQQDEL 1230 H1
..eSSRKSSKSAGSgISTNQSILNAsIHsSSSGGFsAWGVSPQYAVAcp........... 1171 D1
EEeEDERGPTPPVRgAASSPAAVSYsHQsTATLTPsPQEELQPMLQDcpEETGHMQHQPD 1290 H1
................pENVy...sNpl.....SAVAGGTQNRYQITPTNQHPPQl.... 1203 D1
RRRQPVSPPPPPRPISpPHTyGYIsGplVSDMDTDAPEEEEDEADMEVAKMQTRRlLLRG 1350 H1
....paY................FATTGPGGAVPPNHLP.............faTQRHaa 1230 D1
LEQTpaSSVGDLESSVTGSMINGWGSASEEDNISSGRSSVSSSDGSFFTDADfaQAVAaa 1410 H1
SeyQaglNAar................cAQSRACNsCdALATPSPmq............. 1261 D1
Aey.aglKVarRQMQDAAGRRHFHASQcPRPTSPVsTdSNMSAAVmqKTRPAKKLKHQPG 1469 H1
    CYTOPLASMIC MOTIF #3
...........ppppvpVpEGWYQPVHPNSH.PMHpTS.SNHQIYQCSSECsDHSRSsQS 1307 D1
HLRRETYTDDLppppvpPpAIKSPTAQSKTQLEVRpVVVPKLPSMDARTDRsSDRKGsSY 1529 H1
HKrQL.................QLEeHGSSAkQrgGHHRRrA.pVVQPCMESeN......ENM   D1
KGrEVLDGRQVVDMRTNPGDPREAQeQQNDGkGrgNKAAKrDLpPAKTHLIQeDILPYCRPTF   H1
LAEYEQrQYTsDCCNssrEGDTC..........SCSeGSCl..yAeAgePAPRQMTAKNT 1395 D1
PTSNNPrDPSsSSSMssrGSGSRQREQANVGRRNIAeMQVlGGy.eRgeDNNEELEETES 1651 H1
 


Exemplary such Robo specific immunogenic and/or antigenic peptides are shown in Table 2.

TABLE 2
 
Immunogenic Robo polypeptides eliciting Robo-specific rabbit polyclonal
antibody: Robo polypeptide-KLH conjugates immunized per protocol
described below.
  Robo Polypeptide, Sequence Immunogenicity
   
  SEQ ID NO:2, residues 68-77 +++
  SEQ ID NO:2, residues 79-94 +++
  SEQ ID NO:2, residues 95-103 +++
  SEQ ID NO:2, residues 122-129 +++
  SEQ ID NO:2, residues 165-176 +++
  SEQ ID NO:2, residues 181-191 +++
  SEQ ID NO:2, residues 193-204 +++
  SEQ ID NO:2, residues 244-251 +++
  SEQ ID NO:2, residues 274-290 +++
  SEQ ID NO:2, residues 322-331 +++
  SEQ ID NO:2, residues 339-347 +++
  SEQ ID NO:2, residues 407-417 +++
  SEQ ID NO:2, residues 441-451 +++
  SEQ ID NO:2, residues 453-474 +++
  SEQ ID NO:2, residues 502-516 +++
  SEQ ID NO:2, residues 541-553 +++
  SEQ ID NO:2, residues 617-629 +++
   


In addition, species-specific antigenic and/or immunogenic peptides are readily apparent as diverged extracellular or cytosolic regions in Table 1. Human Robo-specific antibodies are characterized as uncross-reactive with non-human Robo polypeptides (SEQ ID NOS:2, 4, 6 and 12). Exemplary such human specific peptides are shown in Table 3.

TABLE 3
 
Immunogenic Robo polypeptides eliciting human Robo-specific rabbit
polyclonal antibody: Robo polypeptide-KLH conjugates immunized per
protocol described below (some antibodies show cross-reactivity with
corresponding mouse/rat Robo polypeptides).
  Robo Polypeptide, Sequence Immunogenicity
   
  SEQ ID NO:8, residues 1-12 +++
  SEQ ID NO:8, residues 18-28 +++
  SEQ ID NO:8, residues 31-40 +++
  SEQ ID NO:8, residues 45-65 +++
  SEQ ID NO:8, residues 106-116 +++
  SEQ ID NO:8, residues 137-145 +++
  SEQ ID NO:8, residues 174-184 +++
  SEQ ID NO:8, residues 214-230 +++
  SEQ ID NO:8, residues 274-286 +++
  SEQ ID NO:8, residues 314-324 +++
  SEQ ID NO:8, residues 399-412 +++
  SEQ ID NO:8, residues 496-507 +++
  SEQ ID NO:8, residues 548-565 +++
  SEQ ID NO:8, residues 599-611 +++
  SEQ ID NO:8, residues 660-671 +++
  SEQ ID NO:8, residues 717-730 +++
  SEQ ID NO:8, residues 780-791 +++
  SEQ ID NO:8, residues 835-847 +++
  SEQ ID NO:8, residues 877-891 +++
  SEQ ID NO:8, residues 930-942 +++
  SEQ ID NO:8, residues 981-998 +++
  SEQ ID NO:8, residues 1040-1051 +++
  SEQ ID NO:8, residues 1080-1090 +++
  SEQ ID NO:8, residues 1154-1168 +++
  SEQ ID NO:8, residues 1215-1231 +++
  SEQ ID NO:8, residues 1278-1302 +++
  SEQ ID NO:8, residues 1378-1400 +++
  SEQ ID NO:8, residues 1460-1469 +++
  SEQ ID NO:8, residues 1497-1519 +++
  SEQ ID NO:8, residues 1606-1626 +++
  SEQ ID NO:8, residues 1639-1651 +++
  SEQ ID NO:10, residues 5-16 +++
  SEQ ID NO:10, residues 38-47 +++
  SEQ ID NO:10, residues 83-94 +++
  SEQ ID NO:10, residues 112-125 +++
  SEQ ID NO:10, residues 168-180 +++
  SEQ ID NO:10, residues 195-209 +++
  SEQ ID NO:10, residues 222-235 +++
  SEQ ID NO:10, residues 241-254 +++
   



The subject domains provide Robo domain specific activity or function, such as Robo-specific cell, especially neuron modulating or modulating inhibitory activity, Robo-ligand-binding or binding inhibitory activity. Robo-specific activity or function may be determined by convenient in vitro, cell-based, or in vivo assays: e.g. in vitro binding assays, cell culture assays, in animals (e.g. gene therapy, transgenics, etc.), etc. The binding target may be a natural intracellular binding target, a Robo regulating protein or other regulator that directly modulates Robo activity or its localization; or non-natural binding target such as a specific immune protein such as an antibody, or a Robo specific agent such as those identified in screening assays such as described below. Robo-binding specificity may be assayed by binding equilibrium constants (usually at least about 107M-1, preferably at least about 108 M-1, more preferably at least about 109 M-1), by the ability of the subject polypeptide to function as negative mutants in Robo-expressing cells, to elicit Robo specific antibody in a heterologous host (e.g a rodent or rabbit), etc.

Similarly, the Comm polypeptide is conveniently selected from Comm polypeptides which specifically modulate Robo expression. Exemplary suitable Comm polypeptides (a) comprise SEQ ID NO:14 or a deletion mutant thereof which specifically modulates Comm expression and/or (b) are encoded by a nucleic acid comprising SEQ ID NO:13 or a nucleic acid which hybridizes with SEQ ID NO:13 under stringent conditions. Suitable deletion mutants are readily screened in Robo down-regulations assays as described below. Preferred Comm domains comprise at least 8, preferably at least 16, more preferably at least 32, most preferably at least 64 consecutive residues of SEQ ID NO:14 and provide a Comm specific activity, such as Comm-specific antigenicity and/or immunogenicity, especially when coupled to carrier proteins as described above for Robo. Exemplary such Comm specific immunogenic and/or antigenic peptides are shown in Table 4.

TABLE 4
 
Immunogenic Comm polypeptides eliciting Comm-specific rabbit
polyclonal antibody: Comm polypeptide-KLH conjugates immunized per
protocol described above.
  Comm Polypeptide, Sequence Immunogenicity
   
  SEQ ID NO:14, residues 1-11 +++
  SEQ ID NO:14, residues 6-17 +++
  SEQ ID NO:14, residues 18-34 +++
  SEQ ID NO:14, residues 35-44 +++
  SEQ ID NO:14, residues 45-63 +++
  SEQ ID NO:14, residues 64-73 +++
  SEQ ID NO:14, residues 74-891 +++
  SEQ ID NO:14, residues 92-109 +++
  SEQ ID NO:14, residues 110-126 +++
  SEQ ID NO:14, residues 127-136 +++
  SEQ ID NO:14, residues 137-151 +++
  SEQ ID NO:14, residues 152-171 +++
  SEQ ID NO:14, residues 172-185 +++
  SEQ ID NO:14, residues 186-199 +++
  SEQ ID NO:14, residues 200-215 +++
  SEQ ID NO:14, residues 216-235 +++
  SEQ ID NO:14, residues 236-250 +++
  SEQ ID NO:14, residues 251-260 +++
  SEQ ID NO:14, residues 261-275 +++
  SEQ ID NO:14, residues 276-288 +++
  SEQ ID NO:14, residues 289-307 +++
  SEQ ID NO:14, residues 308-317 +++
  SEQ ID NO:14, residues 318-331 +++
  SEQ ID NO:14, residues 332-344 +++
  SEQ ID NO:14, residues 345-356 +++
  SEQ ID NO:14, residues 357-370 +++
  SEQ ID NO:14, residues 41-153 +++
  SEQ ID NO:14, residues 117-329 +++
   



The subject domains provide Comm domain specific activity or function, such as Comm-specific cell, especially neuron modulating or modulating inhibitory activity, Comm-ligand-binding or binding inhibitory activity. Comm-specific activity or function may be determined by convenient in vitro, cell-based, or in vivo assays: e.g. in vitro binding assays, cell culture assays, in animals (e.g. gene therapy, transgenics, etc.), etc. The binding target may be a natural intracellular binding target, a Comm regulating protein or other regulator that directly modulates Comm activity or its localization; or non-natural binding target such as a specific immune protein such as an antibody, or a Comm specific agent such as those identified in screening assays such as described below. Comm-binding specificity may be assayed by binding equilibrium constants (usually at least about 107 M-1, preferably at least about 108 M-1, more preferably at least about 109 M-1), by the ability of the subject polypeptide to function as negative mutants in Comm-expressing cells, to elicit Comm specific antibody in a heterologous host (e.g a rodent or rabbit), etc.

In one embodiment, the Comm polypeptides are encoded by a nucleic acid comprising SEQ ID NO:13 or a nucleic acid which hybridizes with a full-length strand of SEQ ID NO:13, preferably under stringent conditions. Such nucleic acids are at least 36, preferably at least 72, more preferably at least 144 and most preferably at least 288 bases in length. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5×SSPE (0.18 M NaCl, 0.01 M NaPO4, pH7.7, 0.001 M EDTA) buffer at a temperature of 42° C. and remaining bound when subject to washing at 42° C. with 0.2×SSPE (Conditions I); preferably hybridizing in a buffer comprising 50% formamide in 5×SSPE buffer at a temperature of 42° C. and remaining bound when subject to washing at 42° C. with 0.2×SSPE buffer at 42° C. (Conditions II). Exemplary nucleic acids which hybridize with a strand of SEQ ID NO:13 are shown in Table 5.

TABLE 5
 
Exemplary nucleic acids which hybridize with a strand of SEQ ID NO:13
under Conditions I and/or II.
  Comm Nucleic Acids Hybridization
   
  SEQ ID NO:13, nucleotides 1-47 +
  SEQ ID NO:13, nucleotides 58-99 +
  SEQ ID NO:13, nucleotides 95-138 +
  SEQ ID NO:13, nucleotides 181-220 +
  SEQ ID NO:13, nucleotides 261-299 +
  SEQ ID NO:13, nucleotides 274-315 +
  SEQ ID NO:13, nucleotides 351-389 +
  SEQ ID NO:13, nucleotides 450-593 +
  SEQ ID NO:13, nucleotides 524-546 +
  SEQ ID NO:13, nucleotides 561-608 +
  SEQ ID NO:13, nucleotides 689-727 +
  SEQ ID NO:13, nucleotides 708-737 +
  SEQ ID NO:13, nucleotides 738-801 +
  SEQ ID NO:13, nucleotides 805-854 +
  SEQ ID NO:13, nucleotides 855-907 +
  SEQ ID NO:13, nucleotides 910-953 +
  SEQ ID NO:13, nucleotides 1007-1059 +
   



A wide variety of cell types express Robo polypeptides subject to regulation by the disclosed methods, including many neuronal cells, transformed cells, infected (e.g. virus) cells, etc. Ascertaining Robo expression is readily effected by antibody staining. Accordingly, indications for the subject methods encompass a wide variety of cell types and function, including axon outgrowth, tumor cell invasion or migration, etc. The target cell may reside in culture or in situ, i.e. within the natural host. For in situ applications, the compositions are added to a retained physiological fluid such as blood or synovial fluid. For CNS administration, a variety of techniques are available for promoting transfer of the therapeutic across the blood brain barrier including disruption by surgery or injection, drugs which transiently open adhesion contact between CNS vasculature endothelial cells, and compounds which facilitate translocation through such cells. Comm polypeptides may also be amenable to direct injection or infusion, topical, intratracheal/nasal administration e.g. through aerosol, intraocularly, or within/on implants e.g. fibers e.g. collagen, osmotic pumps, grafts comprising appropriately transformed cells, etc. A particular method of administration involves coating, embedding or derivatizing fibers, such as collagen fibers, protein polymers, etc. with therapeutic polypeptides. Other useful approaches are described in Otto et al. (1989) J Neuroscience Research 22, 83-91 and Otto and Unsicker (1990) J Neuroscience 10, 1912-1921. Generally, the amount administered will be empirically determined, typically in the range of about 10 to 1000 μg/kg of the recipient and the concentration will generally be in the range of about 50 to 500 μg/ml in the dose administered. Other additives may be included, such as stabilizers, bactericides, etc. will be present in conventional amounts.

In one embodiment, the invention provides administering the subject Comm polypeptides in combination with a pharmaceutically acceptable excipient such as sterile saline or other medium, gelatin, an oil, etc. to form pharmaceutically acceptable compositions. The compositions and/or compounds may be administered alone or in combination with any convenient carrier, diluent, etc. and such administration may be provided in single or multiple dosages. Useful carriers include solid, semi-solid or liquid media including water and non-toxic organic solvents. In another embodiment, the invention provides the subject compounds in the form of a pro-drug, which can be metabolically converted to the subject compound by the recipient host. A wide variety of pro-drug formulations for polypeptide-based therapeutics are known in the art. The compositions may be provided in any convenient form including tablets, capsules, troches, powders, sprays, creams, etc. As such the compositions, in pharmaceutically acceptable dosage units or in bulk, may be incorporated into a wide variety of containers. For example, dosage units may be included in a variety of containers including capsules, pills, etc. The compositions may be advantageously combined and/or used in combination with other therapeutic or prophylactic agents, different from the subject compounds. In many instances, administration in conjunction with the subject compositions enhances the efficacy of such agents, see e.g. Goodman & Gilman 's The Pharmacological Basis of Therapeutics, 9th Ed., 1996, McGraw-Hill.

In another aspect, the invention provides methods of screening for agents which modulate Robo-Comm interactions. These methods generally involve forming a mixture of a Robo-expressing cell, a Comm polypeptide and a candidate agent, and determining the effect of the agent on the amount of Robo expressed by the cell. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds. Identified reagents find use in the pharmaceutical industries for animal and human trials; for example, the reagents may be derivatized and rescreened in in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development. Cell and animal based neural guidance/repulsion assays are described in detail in the experimental section below.

The following experimental section and examples are offered by way of illustration and not by way of limitation.

Experimental

roundabout is Required to Prevent Ipsilateral Axons from Crossing the Midline. Mutations in robo lead to an increase in the number of embryonic CNS axons in the commissures, coincident with a reduction of the number of axons in the longitudinal connectives as observed with MAb BP 102. The two commissures are thicker than normal and partially fuse as they spill over into one another; the longitudinals are thinner and pulled closer together toward the midline. We analyzed the robo mutant phenotype in more detail using the 1 D4 MAb (anti-Fas II) which at stage 13 stains a subset of growth cones (including aCC, pCC, vMP2, MP1, dMP2) and from stages 14-17 stains three major longitudinal axon tracts, including (from medial to lateral) the pCC pathway (pioneered by the pCC growth cone), the MP1 pathway (pioneered by the MP1 growth cone), and a 3rd lateral pathway (Lin et al., 1994; Hidalgo and Brand, 1997). Previous analysis (Seeger et al., 1993) with MAb 1D4 showed that the pCC growth cone, which normally projects anteriorly on its own side near the midline to pioneer the pCC pathway, in robo mutant embryos projects across the midline, fasciculating with its contralateral homologue at the midline. The axon pathway it pioneers—the pCC pathway—which normally projects longitudinally on its own side near the midline, in robo mutant embryos projects back and forth across the midline. The pCC pathway takes on a circular pattern as it joins with the same pathway from the other side and whirls back and forth across the midline, thus defining the phenotype for which the gene was named.

The fuzzy commissure phenotype observed in robo mutant embryos does not appear to be due to changes in cell fates at the midline or elsewhere in the CNS. All of the midline cells are present, and their fates appear normal as assayed with a variety of different markers (Seeger et al., 1993). All of the commissural and longitudinal axon pathways begin in their normal location, but the longitudinal pathways are pulled closer at the midline as axon bundles circle around the midline, and the commissures become fused and fuzzy as too many axons cross the midline. In contrast, in mutants in which all or some of the midline cells die or fail to properly differentiate, the longitudinal pathways either collapse onto the midline or from the outset form closer together than normal (Klämbt et al., 1991; Mayer and Nüsslein-Volhard, 1988). Thus, the defects observed in robo mutant embryos are not due to changes in cell fates but rather result from defects in axon guidance.

We examined in greater detail the behavior of the pCC growth cone in robo mutant compared to wild type embryos. In wild type embryos, the vMP2 cell body lies embedded at the edge of the midline. The pCC growth cone extends anterior to a point just lateral to vMP2's cell body. The pCC growth cone is then met by the lateral extension of vMP2's growth cone, and as pCC extends anteriorly and a bit laterally, the vMP2 growth cone wraps around pCC's axons and extends right behind it (Lin et al., 1994). This tight association of vMP2 and pCC is mediated by Fasciclin II (Fas II), a homophilic cell adhesion molecule (CAM) (Grenningloh et al., 1990, 1991) that is expressed from the beginning of axon outgrowth on the cell bodies, axons, and growth cones of a subset of neurons, including pCC and vMP2. In FasII mutant embryos, vMP2 and pCC no longer tightly associate, and their axons fail to fasciculate (Lin et al., 1994).

If the pCC and vMP2 neurons express Fas II, and their growth cones and axons are so attracted to each other in a Fas II-mediated fashion, why does not pCC's growth cone initially extend more medially toward vMP2's cell body which is a short distance away? The answer appears to be because vMP2's cell body is partly embedded in other midline cells, and thus vMP2's cell body is partly surrounded by the putative midline repellent. In robo mutant embryos, pCC's initial trajectory is directly toward vMP2's cell body, where it adheres to vMP2; pCC's growth cone then crosses the midline, fasciculating with its contralateral homologue at the midline.

roundabout is Required to Prevent Commissural Axons from Recrossing the Midline. The circular pathway taken by the pCC pathway as it crosses back and forth across the midline (as visualized with the anti-Fas II MAb) led us to suggest that some axons were freely recrossing the midline. Although Fas II is expressed on a relatively small subset of axons in the early embryo, and thus we can use it to observe pCC's growth cone abnormal crossing of the midline in robo mutants, the resulting pattern of expression in older embryos becomes quite complicated and it is difficult to resolve precisely which axons are crossing the midline.

To confirm that axons cross and recross the midline freely in robo mutants, we examined the expression of Connectin (Nose et al., 1992), a CAM expressed on a more restricted subset of CNS axons than is Fas II. Connectin is also expressed on motor axons in the segmental nerve. We used the C1.427 MAb to follow Connectin expression (Meadows et al., 1994). Connectin is expressed on the SP1 neuron whose cell body lies near the midline just anterior to the anterior commissure, and just medial to the longitudinal tracts. SP1's growth cone normally projects across the midline, fasciculating with the axon of its contralateral homologue. The growth cone then appears to adhere to the cell body of its contralateral homologue, grows around that cell body, and turns to project anteriorly in a medial sub-fascicle of the pCC pathway.

In robo mutant embryos as in wild type embryos, SP1's growth cone extends across the midline, adheres to the axon and then cell body of its contralateral homologue, and turns to project anteriorly. However, as it extends anteriorly into the next segment, it typically moves toward the midline, apparently attracted towards and adhering to the axon of its contralateral homologue just on the other side of the midline. The two SP1 axons typically join together around the posterior commissure of the next anterior segment. Sometimes they extend together on the left side of the midline and sometimes on the right side, freely crossing and recrossing the midline while fasciculating with the SP1 axons originating from both sides of neighboring segments. These results show that in addition to preventing ipsilaterally projecting axons from crossing the midline, Robo also functions to prevent contralaterally projecting axons from recrossing the midline.

roundabout Controls Crossing of the midline in a Dosage Sensitive Manner. Another axonal marker which labels a very small subset of axons is the Tau-β-galactosidase reporter gene expressed under control of the apterous promoter (called apC; Lundgren et al., 1995). In wild type embryos, the apC-tau-lacZ transgene labels three interneurons per abdominal hemisegment, here called the Ap neurons. The Ap neurons have lateral cell bodies and their growth cones initially project towards the midline. Upon nearing the midline, these growth cones then turn to project anteriorly on their own side along the edge of the midline, fasciculating with each other and with their homologues from neighboring segments; in wild type embryos, they never cross the midline in abdominal segments.

In robo mutant embryos, the Ap axons cross the midline in every segment, join up with their contralateral homologues, and often project anteriorly in one discrete longitudinal fasicle. The Ap fascicle displays two behaviors, usually crossing and recrossing the midline multiple times as a single bundle, or occasionally separating into different bundles of axons which project on one side or the other and independently cross the midline.

We observed a partially penetrant Ap axon phenotype in robo heterozygous embryos. In wild type, none of the 6 Ap axons in each segment ever cross the midline; in robo homozygous mutants, all 6 Ap axons cross the midline. In robo heterozygous mutant embryos, one of the Ap axons is observed crossing the midline in about 30% of segments, which accounts for a penetrance of about 5% of all Ap axons (Table 1). This partially penetrant crossing with 50% of robo indicates a dose requirement for the robo gene product in these axons. Moreover, since the Ap axons extend midway through axonogenesis, once many axon pathways have already been pioneered, these results indicate that robo is required throughout axonogenesis, not just to establish the initial projections of the pioneer axons.

Underexpression of Comm Leads to Increased Levels of Robo Protein. The commissureless (comm) mutant has a complementary phenotype to that of robo in that too few axons cross the midline (Seeger et al., 1993). When visualised with MAb BP102, the axon commissures are noticeably absent. In certain hypomorphic comm alleles (e.g., comm7; Tear et al., 1996), the commissures are not completely absent, but rather partial and highly abnormal axon commissures do form in a few segments (particularly in the thorax). We examined the expression of Robo protein in these comm hypomorphic alleles using the 13C9 anti-Robo MAb (Kidd et al, 1997). Normally, Robo is expressed at very low levels on commissural axons and at high levels on longitudinal axons. In comm mutant embryos, Robo expression in the longitudinal tracts appears even higher than normal. Interestingly, in comm hypomorphic alleles, the occasional thin commissures express Robo protein at levels that are higher than normally seen in the commissures and closer to what is typically seen in the longitudinal tracts. This result was our first hint that Comm protein might function by suppressing Robo expression on commissural axons. Previous studies had shown that comm encodes a novel transmembrane protein that is expressed by the midline glia and that is apparently transferred to commissural axons (Tear et al., 1996). Given these results, we wondered whether expression of comm in all neurons might reduce Robo levels and lead to a robo phenotype.

Overexpression of Comm generates a robo-Like Phenotype. To test the hypothesis that increased expression of comm might lead to a robo-like phenotype, we used the UAS-GAL4 system (Brand and Perrimon, 1993) to change the pattern of comm expression. We generated UAS-comm transgenic lines and drove expression pan-neurally using the sca-GAL4 line. Since flies carrying a copy of both the driver and effector transgenes are viable, we used them as parents and examined their progeny. A continuous range of robo-like phenotypes was observed with MAbs BP102 and 1 D4. The range of phenotypes reveals the comm gain-of-function phenotype to be dosage sensitive, as the severity increased in embryos carrying two copies of both transgenes as compared to embryos carrying only one copy of each.

Superficially, the robo phenotype can be mimicked by mutants causing inappropriate migration or cell death of the midline glia, both of which result in fuzzy commissures (Klämbt et al., 1991). However, such phenotypes are not visible until midway through axonogenesis, and are easily detected by examining early axon behavior. In addition, we stained the embryos with a MAb raised against 8H 11, a protein expressed specifically by the midline glia, and confirmed that the midline glia are still present

In the embryos ectopically expressing comm, Fas II positive axons, such as pCC, were found to behave identical to how they behave in robo mutants. When Comm is overexpressed, the pCC growth cone extends towards the vMP2 cell body, and then across the midline, just as it does in a robo mutant. In the comm gain-of-function, the pCC fascicle freely crosses and midline and forms the same circles or whirls as it does in the robo loss-of-function.

Overexpression of Comm Leads to Reduced Levels of Robo Protein. Having established that the comm overexpression generates a bona fide robo-like axon guidance phenotype, we next examined Robo expression in these embryos using the anti-Robo MAb 13C9. The sca-GAL4 driver begins driving expression in the neuroepithelium before axon outgrowth (˜stage 9) has begun and switches off by stage 13; sca-GAL4 does not express in the epidermis. In wild type embryos, the pattern of Robo protein expression begins in the neuroepithelium, as well in some lateral epidermal stripes, but is conspicuously absent from the midline region. In comm gain-of-function embryos, Robo expression in the neuroepithelium is greatly reduced or absent, while the epidermal expression outside the nervous system is maintained. This same pattern can be observed around the time when the first growth cones are extending. In wild type embryos during stages 12 and 13, no Robo is seen at the midline, but there is a high level of Robo expression on ipsilaterally projecting growth cones such as pCC and a significant level throughout the neuroepithelium. In contrast, in comm gain-of-function embryos, the pCC growth cone lacks Robo protein and the neuroepithelium expresses greatly reduced levels of Robo.

The dramatic reduction in the levels of Robo were observed until about stage 14, coincident with the sca-GAL4 driver ceasing expression. In the sca-GAL4; UAS-robo embryos, Robo protein begins to accumulate throughout the CNS after stage 14, reaching significant levels (but still below wild type) by stage 16. Interestingly, in these transgenic embryos, although we observe some Robo-positive axons in the commissures at later stages, Robo expression remains higher in longitudinal tracts. We interpret the Robo-positive axons in the commissures as later axons following misguided pioneer axons; fasciculation with the pioneers allows these Robo-positive axons to cross the midline in spite of modest levels of Robo.

The elav-GAL4 line also expresses pan-neurally but only in post-mitotic neurons; it begins driving expression of UAS transgenes during stage 12 and remains expressed throughout the rest of embryogenesis. Ectopic expression of comm by elav-GAL4 led to a less severe version of the robo phenotype. We interpret this weaker phenotype as being due to either a weaker overall level of Comm expression or because increased Comm initiates after the pioneers have already established the initial pathways. In addition, since sca-GAL4 drives expression in midline glia, the source of normal comm expression, while elav-GAL4 does not drive expression in the midline glia, the possibility exists that the less severe phenotype of the elav transgene is due to this lack of midline comm expression.

To address this issue, we attempted to increase the level of Comm specifically at the midline using multiple GAL4 lines, including sim-GAL4, slit-GAL4, F63-GAL4, and p52A-GAL4, all of which express at the midline during the period of commissure formation. When UAS-comm was expressed by any of these four lines, only very weak BP 102 phenotypes were observed, although because most of these inserts are homozygous lethal, we have not been able to easily increase the dosage with these lines to comparable levels as with the sca-GAL4 line. None of these gain-of-function phenotypes was as strong as that observed with the sca-GAL4 line. We also cannot rule out that these differences in the strength of the gain-of-function phenotypes using different GAL4 lines do not reflect differences in timing, levels of expression, or location of expression within the CNS.

We conclude that the normal function of comm is to down-regulate the low level of Robo expression present on commissural axons, thereby allowing them to cross the midline. Increasing levels of Comm in the CNS lead to more severe robo-like phenotypes, indicating a dosage sensitivity. This sensitivity to dosage is also reflected in the behavior of Ap axons in robo heterozygotes, thus showing a parallel dosage sensitivity by either decreasing Robo or increasing Comm.

These results indicate that control of Robo expression is complex and highly regulated from transcription to translation to post-translational. We show that there is an inverse correlation between Comm expression and Robo expression. In wild type embryos, Comm is expressed at the midline, and Robo expression is very low on commissural axons crossing the midline. In comm hypomorphic mutant embryos, those few axons that do cross the midline now express higher levels of Robo protein. In comm gain-of-function embryos (using transgenic constructs that drive over- and ectopic expression of comm), the overall levels of Robo are dramatically decreased wherever increased Comm expression coincides with Robo expression. Furthermore, using certain GAL4 lines that drive transient comm expression, we observe that once Comm disappears in older embryos, Robo protein expression begins to increase towards its normal levels. Thus, Comm down-regulates Robo expression in a very tight fashion.

Only a small amount of Comm is normally expressed at the midline. The midline also expresses high levels of a putative repellent that is the ligand for the Robo receptor. Growth cones that express high levels of Robo, such as ipsilaterally projecting growth cones from the outset or commissural growth cones once they cross the midline, are relatively immune to significant down-regulation by the normally low levels of midline Comm and thus are prevented from crossing the midline. Only abnormally high levels of Comm (using transgenes that drive overexpression) are sufficient to down-regulate this Robo expression to a level that allows these growth cones to cross the midline. In contrast, growth cones that normally express lower levels of Robo (i.e., those commissural growth cones that cross the midline in the presence of Comm) are highly sensitive to Comm, in that the normal low levels of Comm can further reduce their levels of Robo and thus allow them to cross the midline. In the absence of Comm, these growth cones can not cross the midline, due to their low levels of Robo; in the robo; comm double mutant they all freely cross.

Genetic Stocks. All robo alleles were isolated on chromosomes deficient for Fasciclin III as described in Seeger et al., 1993. The robo phenotype is independent of the absence of FasIII.

Protein Immunocytochemistry. Immunocytochemistry was performed as described by Patel (1994). For anti-Robo staining, MAb 13C9 was diluted 1:10 in PBS with 0.1% Tween-20, and the embryos were fixed and cracked so as to minimize exposure to methanol. The presence of triton and storage of embryos in methanol were both found to destroy the activity of MAb 13C9. For anti-Connectin staining with MAb C1.427, the embryos were fixed in 3.7% formaldehyde/PEM buffer (100 mM PIPES, 2 mM EGTA, 1 mM MgSO4); C1.427 was diluted 1:10 in PBS with 0.1% Triton. The apterous-tau-lacZ embryos were hand devitellinized and dissected on poly-lysine coated slides and subsequently fixed for 20 minutes with 3.7% formaldehyde; rabbit anti-β-galactosidase (Cappell) was used at 1:10,000 and biotinylated anti-rabbit secondary was used at 1:1000 and enhanced with the Vectastain Elite ABC kit (Vector Laboratories).

Transformation of Drosophila, robo rescue and overexpression. The comm cDNA was inserted as a 1.7 kb XhoI-XbaI fragment into the XhoI and Xba sites of pUAST (Brand and Perrimon, 1993). Transformant lines were generated and mapped by standard procedures.
 


Claim 1 of 22 Claims

1. A method of promoting axon outgrowth of a neuron determined to have expressed on its surface an amount of a natural human Robo and to be subject to an axon outgrowth repulsion mediated by the Robo, said method comprising the step of contacting the neuron with a natural Comm in an amount and under conditions sufficient to reduce the amount of Robo expressed on the neuron, wherein the Comm is provided to the neuron exogenously in a pharmaceutically acceptable composition, whereby the amount of Robo expressed on the surface is reduced, thereby reducing the outgrowth repulsion mediated by the Robo, and thereby promoting the axon outgrowth of the neuron.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

     
[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]